تالیفات

 

Cost-EffectivenessAnalysisofTocilizumabinComparisonwith Infliximab inIranianRheumatoidArthritisPatientswith Inadequate ResponsetotDMARDs:AMultistageMarkovModel

Authers: Amir Hashemi-Meshkini, PharmD1, ShekoufehNikfar, PharmD, PhD1, ElizabethGlaser, MS, MA2, Ahmadreza Jamshidi, MD3, SeyedAlirezaHosseini, PharmD, PhD1, 4, *

Abstract: To analyzethecost-effectivenessoftwocommontreat- ment strategiesinIran,comparinginfliximab plusmethotrexatewith tocilizumab plusmethotrexateinpatientswithrheumatoidarthritis with inadequateresponsetotraditionaldisease-modifyinganti- rheumatic drugs. Methods: A multistageMarkovdecisionmodel was appliedtoassesstheincrementalcost-effectivenessratio(ICER) of atocilizumab-containingregimenversusaninfliximab-containing regimen overa5-yeartimeperiod.Inthecaseofnoresponse,we assumed thatpatientsswitchedtothenexttreatment(adalimumab, rituximab, orsupportivecare)insequenceforeachstrategy.We consideredmajorcostitems,suchasdirectmedicalcostsanddirect nonmedical costs,fromapayer(patientsandthird-partypayers) perspective.Adeterministicsensitivityanalysiswasconductedto assess therobustnessofthemodelresultsovertheuncertaintyofkey parameters. Results: In thebase-caseanalysis,theICERofthe tocilizumab-containingregimenwasUS$60,800perquality-adjusted life-year ascomparedtotheinfliximab-containingregimen.In the sensitivityanalysis,changesinthepriceofthedrugsby generic substitution,inutilityscores,andindiscountratedidnot change ouroverallconclusions.Amongallinputstotheprimary study andthesensitivityanalyses,however,thepriceoftocili- zumab hadthemostimpactontheICER. Conclusions: Although tocilizumab andmethotrexateprovidealargergaininquality- adjusted life-years,theircurrentpriceisquitehighascomparedwith those ofourotherinterventions.Therefore,aregimencontaining tocilizumab isnotcost-effectiveascomparedwithaninfliximab- containingregimenforpatientswithrheumatoidarthritisinIran. Keywords: cost-effectiveness,infliximab, Iran,rheumatoidarthritis, tocilizumab. سال انتشار: 2015
 

Cost-EffectivenessAnalysisofTocilizumabinComparisonwith Infliximab inIranianRheumatoidArthritisPatientswith Inadequate ResponsetotDMARDs:AMultistageMarkovModel

Authers: Amir Hashemi-Meshkini, PharmD1, ShekoufehNikfar, PharmD, PhD1, ElizabethGlaser, MS, MA2, Ahmadreza Jamshidi, MD3, SeyedAlirezaHosseini, PharmD, PhD1, 4, *

Abstract: To analyzethecost-effectivenessoftwocommontreat- ment strategiesinIran,comparinginfliximab plusmethotrexatewith tocilizumab plusmethotrexateinpatientswithrheumatoidarthritis with inadequateresponsetotraditionaldisease-modifyinganti- rheumatic drugs. Methods: A multistageMarkovdecisionmodel was appliedtoassesstheincrementalcost-effectivenessratio(ICER) of atocilizumab-containingregimenversusaninfliximab-containing regimen overa5-yeartimeperiod.Inthecaseofnoresponse,we assumed thatpatientsswitchedtothenexttreatment(adalimumab, rituximab, orsupportivecare)insequenceforeachstrategy.We consideredmajorcostitems,suchasdirectmedicalcostsanddirect nonmedical costs,fromapayer(patientsandthird-partypayers) perspective.Adeterministicsensitivityanalysiswasconductedto assess therobustnessofthemodelresultsovertheuncertaintyofkey parameters. Results: In thebase-caseanalysis,theICERofthe tocilizumab-containingregimenwasUS$60,800perquality-adjusted life-year ascomparedtotheinfliximab-containingregimen.In the sensitivityanalysis,changesinthepriceofthedrugsby generic substitution,inutilityscores,andindiscountratedidnot change ouroverallconclusions.Amongallinputstotheprimary study andthesensitivityanalyses,however,thepriceoftocili- zumab hadthemostimpactontheICER. Conclusions: Although tocilizumab andmethotrexateprovidealargergaininquality- adjusted life-years,theircurrentpriceisquitehighascomparedwith those ofourotherinterventions.Therefore,aregimencontaining tocilizumab isnotcost-effectiveascomparedwithaninfliximab- containingregimenforpatientswithrheumatoidarthritisinIran. Keywords: cost-effectiveness,infliximab, Iran,rheumatoidarthritis, tocilizumab. Copyright & 2015, سال انتشار: 2016
 

The Effects of Isolated Hip Abductor and External Rotator Muscle Strengthening on Pain, Health Status, and Hip Strength in Females With Patellofemoral Pain: A Randomized Controlled Trial

Authers: KHALIL KHAYAMBASHI, PT, PhD1 • ZEYNAB MOHAMMADKHANI, MS2 • KOUROSH GHAZNAVI, MD3, MARK A. LYLE, PT, OCS4 • CHRISTOPHER M. POWERS, PT, PhD5

Abstract: TTSTUDY DESIGN: Randomized controlled trial. TTOBJECTIVES: To examine the effectiveness of isolated hip abductor and external rotator strengthening on pain, health status, and hip strength in females with patellofemoral pain (PFP). TTBACKGROUND: Altered hip kinematics resulting from hip muscle weakness has been proposed as a contributing factor in the development of PFP. To date, no study has examined clinical outcomes associated with isolated hip muscle strengthening in those with PFP. TTMETHODS: Twenty-eight females with ... سال انتشار: 2012
 

Causes of Blindness in Ocular Behçet’s Disease Comparing the End-Blinding Results in Two Genders

Authers: Hormoz Chams, MD1 • Hassan Behboudi, MD2 • Fariba Ghassemi, MD3 Fereydoun Davatchi, MD4 • Farhad Shahram, MD4 • Sheyda Chams-Davatchi, MD5

Abstract: To investigate and compare the causes of blindness in ocular Behçet’s disease (BD) in men and women Methods: In a retrospective, descriptive investigation from 1976 to 2008, 6,021 BD cases were registered in our BD Unit of Shariati Hospital of Tehran University of Medical Sciences (TUMS). At the last visit, 187 patients (124 men and 63 women) were blind (vision=1/10 or less) at least in one eye and with at least ... سال انتشار: 2012